Abstracts Archive - Page 1605 of 2425 - ACR Meeting Abstracts

Abstract Number: 2820 • 2016 ACR/ARHP Annual Meeting
Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis
Samantha Stanley¹, Huihua Ding², Claudia Pedroza³, Ramesh Saxena⁴, Michelle Petri⁵ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁴Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An aptamer-based screening assay was used to analyze the levels of 1129 different proteins in 24 human urine samples (8 active lupus nephritis (LN),…
Abstract Number: 2821 • 2016 ACR/ARHP Annual Meeting
Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?
Chi Chiu Mok¹, Ling Yin Ho², Chi Hung To³ and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To evaluate whether hyperuricemia is independently associated with cardiovascular events in a cross-sectional study of Chinese patients with SLE. Methods: Consecutive patients who fulfilled…
Abstract Number: 2822 • 2016 ACR/ARHP Annual Meeting
Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok¹, Eric Bro², Ling Yin Ho³, Ravinder Singh² and Paul Jannetto⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ⁴Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the relationship between serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients. Methods:…
Abstract Number: 2823 • 2016 ACR/ARHP Annual Meeting
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Chi Chiu Mok¹, Samar Soliman², Ling Yin Ho³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: Proteomic screening is an efficient approach for identifying protein biomarkers in various inflammatory diseases. Our preliminary proteomic analysis revealed elevated levels of urinary angiostatin,…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2825 • 2016 ACR/ARHP Annual Meeting
Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis
Sanat Phatak, Smriti Chaurasia, Shravan Mishra, Ranjan Gupta, Amita Aggarwal and Ramnath Misra, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: B cell Activating Factor of the TNF Family (BAFF) and A Proliferation Inducing Ligand (APRIL) help B cell activation, maintenance and plasma cell survival.…
Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
Sen Hee Tay¹, Anna-Marie Fairhurst² and Anselm Mak¹, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
Abstract Number: 2827 • 2016 ACR/ARHP Annual Meeting
Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Kamalanathan Sambandam⁴, Eliza Chakravarty¹, Judith A. James⁵ and Joan T. Merrill⁶, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
Abstract Number: 2828 • 2016 ACR/ARHP Annual Meeting
Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up
Sejin Byun¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Even though the survival rate among SLE patients has improved over the past few decades, the mortality rate caused by the acute flare of…
Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis
Eleana Ntatsaki¹, Alba Velo Garcia², Alan D. Salama³ and David A. Isenberg⁴, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
Abstract Number: 2830 • 2016 ACR/ARHP Annual Meeting
Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
Laura Durcan¹, Armin Zadeh², Margery Connelly³, James Otvos³, Laurence S Magder⁴ and Michelle Petri⁵, ¹University of Washington, Seattle, WA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³LabCorp, Raleigh, NC, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with atherosclerotic cardiovascular (CV) disease and related mortality. This is contributed to, but cannot be fully explained, by traditional…
Abstract Number: 2831 • 2016 ACR/ARHP Annual Meeting
Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus
Hwee-Siew Howe¹, Bernard Thong², Kok Ooi Kong³, Hiok-Hee Chng², Tsui Yee Lian², Faith Chia², Karine Tay², Tang Ching Lau⁴, Weng Giap Law², Ee Tzun Koh⁵ and Bernard Pui Lam Leung^6,7, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SINGAPORE, Singapore, ²Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ³Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine,, National University of Singapore, ., Singapore, ⁵Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ⁶Physiology, National University of Singapore, ., Singapore, ⁷Rheumatology, Allergy & Immunology, Tan Tock Seng Hospital, ., Singapore
Background/Purpose: B cell activating factor (BAFF) is implicated in the pathogenesis of systemic lupus erythematosus (SLE). A previous small scale study reported that endogenous neutralizing…
Abstract Number: 2832 • 2016 ACR/ARHP Annual Meeting
Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus
Dag Leonard¹, Andrei Alexsson¹, Johanna Dahlqvist², Kimberly Taylor³, Johanna K Sandling⁴, Christine Bengtsson⁵, Elisabet Svenungsson⁶, Christopher Sjöwall⁷, Andreas Jönsen⁸, Iva Gunnarsson⁶, Anders A. Bengtsson⁸, Solbritt Rantapaa-Dahlqvist⁵, Maija-Leena Eloranta¹, Ann-Christine Syvänen⁴, Lindsey A. Criswell⁹ and Lars Rönnblom¹, ¹Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ²Uppsala University, Department of Medical Biochemistry and Microbiology Science for Life Laboratory, Uppsala, Sweden, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Uppsala University, Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala, Sweden, ⁵Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden, ⁶Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ⁷Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ⁸Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Methods: An association between a locus located on chromosome 14 and stroke/TIA was shown in both the Swedish (OR 1.8, p=0.0002) and the US…
Abstract Number: 2833 • 2016 ACR/ARHP Annual Meeting
Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE
Helena Tydén¹, Christian Lood², Andreas Jönsen³, Birgitta Gullstrand⁴, Bjorn Dahlback⁵ and Anders A. Bengtsson³, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁴Department of Clinical Sciences, Division of Rheumatology, Lund University, Lund, Sweden, ⁵Department of Translational Medicine, Division of Clinical Chemistry, Lund University, Skane University Hospital Malmö, Malmö, Sweden
Background/Purpose: Human apoM is a 25kDa apolipoprotein present in 5% of HDL particles in plasma. In mouse models, apoM is antiatherogenic and vasculoprotective and…
Abstract Number: 2834 • 2016 ACR/ARHP Annual Meeting
Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Jorge Medina-Rosas¹, Murray Urowitz², Jiandong Su³, Dafna D Gladman⁴ and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The diagnosis of Neuropsychiatric Events (NPE) in SLE is challenging and it is mainly based on the physician judgment. Structural brain imaging has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].